SURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of tirzepatide 15 mg or MTD (10 mg or 15 mg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback